Abstract library

122 results for "supportive care".
#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: RN Gladys Grance
#731 Gastroenteropancreatic (GEP) Neuroendocrine Tumors, Epidemiology and Clinical Retrospective Study from a Tertiary Care Center in North India
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasm derived from peptide- and amine-producing cells of the neuroendocrine system, characterized by the intracellular presence of markers of endocrine tissue, like chromogranin A, synaptophysin, neuronspecific enolase and having low to medium malignant potential.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Dipanjan Panda
Authors: Panda D, Jwada D, Yadav V, Sarin S K, ...
#1885 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with a neuroendocrine tumour (NET) frequently experience physical and psychosocial complaints. Novel strategies to provide information to optimize supportive care in these patients are of interest.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: drs Ld de Hosson
#2100 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design
Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Vincent Hautefeuille
Authors: Gueguen D, Hammel P, ...
#881 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with neuroendocrine tumors (NET) frequently experience physical and psychosocial complaints. Optimal patient information can form an essential aspect of supportive care. To give NET patients continuous access to information, we developed a web-based tailored information and support system.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: MD Grietje Bouma
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#323 Efficacy and Safety of Everolimus in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET): Japanese Subgroup Analysis of RADIANT-3
Introduction: Everolimus, an oral inhibitor of mTOR, significantly improved progression-free survival (PFS) v. placebo in a phase III trial (RADIANT-3) in patients with advanced pNET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Takuji Okusaka
Authors: Okusaka T, Ito T, Ikeda M, Tajima T, ...
#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Mónica Inês
Authors: Soares M, Inês M, Contente M, ...
#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Huib Scheijbeler